Home / David L. Joffe, BSPharm, CDE, FACA (page 44)

David L. Joffe, BSPharm, CDE, FACA

(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

How the Liver Affects Insulin and Vice Versa: Part 2, Obesity and Lipid Metabolism

Andre McMahon, PharmD Candidate, University of Florida College of Pharmacy Dave Joffe, Editor-in-chief, Diabetes In Control The metabolic syndrome is associated with many risk factors for type 2 diabetes mellitus and cardiovascular complications which include: central obesity, elevated fasting glucose, elevated triglycerides, decreased high-density lipoprotein (HDL) cholesterol, and hypertension. When a …

Read More »

GLP-1: Actions on Beta-cell Mass and Function


David Joffe, BSPharm, CDE Tina Burge, PharmD Candidate Florida A&M University Kiet Ngo, Pharm D Candidate Mercer University Abnormalities in incretin hormones such as the glucagon-like peptide-1 (GLP-1) contribute to the development of hyperglycemia. GLP-1 was discovered as a peptide encoded by the proglucagon gene and was named glucagon-like because …

Read More »

DPP-4 Inhibitor Survey


During my frequent visits to prescribers’ offices I get a chance to see their prescribing habits. When it comes to DPP-4 inhibitors, medical professionals seem to have similar opinions on how to use each of the drugs from this class. But to test this theory, we contacted 25 primary care …

Read More »

Early Use of Insulin to Improve Beta Cell Preservation


By David Joffe, BSPharm, CDE; Steve Freed, BSPharm CPT; Brandon Flohr, PharmD, and Vanessa Cepero, PharmD, CVS Pharmacy Type 2 diabetes is a heterogeneous disorder, characterized by glucotoxicity, beta cell dysfunction and decreased insulin sensitivity. Presence of amyloid deposits in the islets and decreased beta cell mass are the pathological hallmark …

Read More »

BD NANO Pen Needle


    Reviewed by Dave Joffe, CDE, FACA, Editor-in-Chief and Katie Maneely, PharmD Intern, University of Florida   The new BD Nano Pen Needles are much smaller than the original BD needles. These new needles are both shorter (4mm) and thinner (32G) than standard needles, potentially offering a less painful way …

Read More »